BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF (ARCA: XBB)

Latest news for BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF (ARCA:XBB)

The Fund is newly organized, non-diversified and seeks to track the investment results of the ICE BofA BB US Cash Pay High Yield Constrained Index (the Index), which contains all bonds in the ICE BofA US Cash Pay High Yield Index (the Underlying Index) that are rated BB1 though BB3, based on an average of Moodys Investors Services, Inc. (Moodys), S&P Global Ratings (S&P) and Fitch Ratings, Inc. (Fitch), but caps issuer exposure at 2 percent. Index constituents are capitalization-weighted, based on their current amount outstanding, provided the total allocation to an individual issuer does not exceed 2 percent. Issuers that exceed the limit are reduced to 2 percent and the face value of each of their bonds is adjusted on a pro-rata basis. Similarly, the face values of bonds of all other issuers that fall below the 2 percent cap are increased on a pro-rata basis. In the event there are fewer than 50 issuers in the Index, each is equally weighted and the face values of their respective bonds are increased or decreased on a pro-rata basis.

BondBloxx BB Rated USD High Yield Corporate Bond ETF

Biotech

News

Penny Stocks

Health Care

Small Cap

Media

Trading Ideas

General

APLS

ARDX

FOLD

IMGN

IPSEY

LGND

MGNX

PRVB

SCYX

SGEN

SPPI

TVTX

VERU

YMAB

Editor&#39;s note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics&#39; Biologics License Application. 

Provention Bio&#39;s Second Try, Apellis&#39;s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November&#39;s Key PDUFA Catalysts Biotech Investors Must Know

BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF

WIIM

AMREP shares are trading higher following Q1 earnings, reported late Friday.

STRO

Sutro Biopharma shares are trading lower. The company announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin in combination with bevacizumab for patients with epithelial ovarian cancer in a poster presentation at the 2024 ESMO Congress.

SNOA

Sonoma Pharmaceuticals shares are trading higher after the company was granted FDA 510(k) clearance for its microdacyn wound care solution.

Sterling Bancorp shares are trading lower after the company announced the sale of Sterling Bank and Trust F.S.B. to EverBank Financial Corp. Also, the company adopted a plan of dissolution and expects to wind down as quickly as possible after the sale.

BILL Holdings (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bill#NYSE">BILL</a>) shares have outperformed the Zacks Computer &amp; Technology sector and its Zacks Internet - Software industry peer Intuit (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intu#NASDAQ">INTU</a>) in the past month.
While BILL has moved up 5.7%, Intuit has risen 0.3%. The broader sector has dropped 0.8% over the same timeframe.
BILL&#39;s robust price performance has been driven by its impressive fiscal fourth-quarter 2024 results.
It registered 16% year-over-year growth in revenues. Core revenues, which included subscription and transaction fees, also rose 16% to $301 million. The upside was supported by BILL&#39;s ability to acquire new customers and expand its payment offerings.
<div class="chart_embed">
<h3>BILL Holdings, Inc. Price and Consensus</h3>
<img alt="BILL Holdings, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/c0/1726494702.png" style="height:283px; width:620px" title="" />
BILL Holdings, Inc. price-consensus-chart | BILL Holdings, Inc. Quote
BILL added a total of 11,300 net new customers in fourth-quarter fiscal 2024, with 4,600 customers from its direct and accounting channels and 6,700 from financial institutions. The retention rate for BILL standalone customers was 83%, demonstrating strong customer loyalty.
Nevertheless, investors should ask this question &mdash; will expanding clientele make BILL shares a good investment? Let&#39;s analyze.
</div>
<h3>Will BILL&#39;s Strong Portfolio Aid Prospect?</h3>
BILL is solidifying its position in the financial technology landscape with a growing portfolio and strong momentum across its Spend &amp; Expense solution.
In fourth-quarter fiscal 2024, BILL upgraded its payment engine and platform, revamped its mobile app and added local transfer options for international payments and FedNow support for instant transfers. This shows BILL&#39;s dedication to enhancing its financial solutions.
In the same quarter, its solutions were utilized by 475,600 businesses and transacted $76 billion in total payment volume.
The Spend and Expense solution (formerly known as Divvy) saw revenue growth of 26%, driven by a 28% increase in card payment volume. This solution added 1,300 net new businesses in fourth-quarter fiscal 2024.
BILL&#39;s expanding SMB clientele with the likes of Adyen (OTC: <a class="ticker" href="https://www.benzinga.com/stock/adyey#OTC">ADYEY</a>), Regions Financial (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rf#NYSE">RF</a>) and Xero has been a key catalyst.
In June, the company partnered with Regions Bank to launch Regions CashFlowIQSM, a digital solution designed to streamline payments and enhance cash-management processes for commercial clients.
BILL&#39;s partnership with Adyen integrates advanced acquiring and issuing capabilities into its financial operations platform for SMBs, enhancing accounts payable and receivable solutions with Adyen&#39;s technology.
<h3>BILL&#39;s Q1 Outlook Looks Dull</h3>
Bill Holdings&#39; strong demand for its financial operations platform among SMBs is boosting top-line growth. However, a challenging macroeconomic environment, persistent inflation and high interest rates are a major concern as SMBs tighten their spending budgets on digital initiatives.
For first-quarter fiscal 2025, BILL expects revenues to be between $346 million and $351 million, indicating growth of 13-15% year over year. The Zacks Consensus Estimate is pegged at $348.07 million, suggesting a rise of 14.13% year over year.
Non-GAAP earnings per share are expected to be between 48 cents and 51 cents. The consensus mark for earnings declined 5.7% in the past 30 days to 49 cents.
<h3>BILL Stock &ndash; Buy, Sell or Hold?</h3>
BILL stock is not so cheap, as the Value Score of D suggests a stretched valuation at this moment.
The forward 12-month Price/Sales ratio for BILL stands at 4.32X, higher than its Zacks Internet - Software sector&#39;s 3.12X, reflecting a stretched valuation.
BILL Holdings currently carries Zacks Rank #3 (Hold) suggesting that it may be wise to wait for a more favorable entry point in the stock.
<a href="https://www.zacks.com/stock/news/2336690/bill-surges-6-in-a-month-should-you-buy-hold-or-sell-the-stock?cid=CS-BENZ-FT-analyst_blog|rank_focused-2336690">To read this article on Zacks.com click here.</a>

Earnings

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Mid Cap

Offerings

Markets

Analyst Ratings

ADYEY

BILL

INTU

BILL Surges 6% in a Month: Should You Buy, Hold or Sell the Stock?

<a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K233399" title="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K233399">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K233399</a>

Sonoma Pharmaceuticals Has Been Granted FDA 510(k) Clearance For Its Microdacyn Wound Care Solution

Watching Packaging Corporation of America, International Paper; Shares See Spike In Price As Citi Reported Cascades Announced A Containerboard Price Increase Effective Oct. 7; $40/Ton Linerboard Increase, $70/Ton Corrugating Medium Increase, $40/Ton Increase In Its White-Top Linerboard; Traders Circulate Other Containerboard Manufactures Could See A Price Increase

A recent post on the Bogleheads Forum illuminated a <a href="https://www.benzinga.com/personal-finance/24/07/39577621/we-are-56-54-with-450-000-income-and-5-1-million-portfolio-but-live-in-a-pricey-area-with-our-14">common dilemma</a> for those nearing retirement: deciding whether to retire early.
A 57-year-old user, currently single and living in a low-cost-of-living area with no debt and a paid-off home, is contemplating retirement. With a current net worth of approximately $1.3 million, the user is trying to determine the right time to retire.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>
Financial Overview
The user's financial situation includes:
• $750K in a 457(b) plan
• $275K in a Roth IRA
• $275K in after-tax accounts
• $30K in savings
All investments, except savings, are allocated in a 60/40 portfolio. The user plans to rely on a pension of $65K annually starting at age 60, which includes a 3% cost-of-living adjustment after the first four years. Social Security benefits of $6K annually are expected to begin at age 70.
The current spending is around $60K per year, though the user only spends $40K and is looking to add some extra cash for more enjoyable activities.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
Key Concerns:
<ul>
<li>Health care Costs: The user will need to secure health care through the ACA exchange, estimated to cost about $500 per month.</li>
</ul>
<ul>
<li>Daily Activities: The user is uncertain about how to fill the next 30 years and plans to start volunteering while pursuing interests like playing in bands.</li>
</ul>
<ul>
<li>Decision to Retire: The user is seeking reassurance about the decision to retire now rather than work another year to slightly improve financial security.</li>
</ul>
See Also: The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a>
The Bogleheads forum responses offered <a href="https://www.benzinga.com/personal-finance/24/07/40041316/laugh-all-you-want-robert-kiyosaki-rich-dad-poor-dad-warns-millions-of-401-k-s-and-iras-will-be-">various perspectives</a> and reassurances:
Forum members assured the user that their financial situation is secure enough to support early retirement. The pension, despite its lack of inflation adjustment in the initial years, along with existing investments, should comfortably cover expenses.
Regarding boredom, suggestions ranged from finding fulfilling activities and hobbies to maintaining flexible plans. Volunteering and other hobbies like playing guitar were noted as great ways to stay engaged.
Trending: This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a>
Several users emphasized that retiring is deeply personal and not purely financial. They advised considering whether the current work is enjoyable or a source of stress. The consensus was that if financial concerns are minimal and personal fulfillment is prioritized, <a href="https://www.benzinga.com/personal-finance/24/05/38761475/retire-early-or-retire-rich-man-asks-whether-its-better-to-retire-at-40-with-125-000-a-year-or-a">retiring now could be a wise choice</a>.
Overall, the majority agreed that the user is financially prepared to retire and should focus on what will bring personal satisfaction.&nbsp;
Retiring is as much about <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">personal readiness and happiness</a> as it is about finances. As one forum member aptly noted, "The only thing you can't buy is more time, so would you rather spend it working or doing whatever YOU want?"
Read Next:
<ul>
<li>Want to invest in homes?<a href="https://www.benzinga.com/money/realbricks"> $100 is enough on this platform</a> that lets you cash out whenever you want.  </li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>

Personal Finance

I'm A Single 57-Year-Old With No Debt, $1.3 Million In Savings, And $65,000 Pension – Can I Retire Early?

Children&#8217;s Place, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) shares are pulling back Monday following large gains after the company posted a <a href="https://www.benzinga.com/news/earnings/24/09/40818077/whats-going-on-with-childrens-place-stock-after-q2-earnings">second-quarter earnings beat last week.</a>
The Details:
Children's Place shares jumped last week following the company's second-quarter earnings release. Children's Place beat earnings expectations, though quarterly sales declined, which the company attributed to cost-cutting measures, significantly improved profitability. 
Additionally, stores saw a positive comparable store sales result for the first time since 2021, driven by stronger units per transaction and conversion metrics and improving traffic trends, while wholesale business rebounded with double-digit growth.&nbsp;&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/09/40856610/why-temu-parent-pdd-holdings-stock-is-down">Why Temu Parent PDD Holdings&#8217; Stock Is Down</a>
Though Children's Place stock is pulling back Monday, it remains up by more than 160% over the past five days. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Children's Place shares are trading well-above the stock&#8217;s 50-day moving average of $7.31 and 53.68% of shares are being sold short which may be contributing to the volatility. 
<h3 class="wp-block-heading">How To Buy PLCE Stock: </h3>
By now you're likely curious about how to participate in the market for Children&#8217;s Place &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
PLCE Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Children's Place shares are down 16.2% at $12.17 at the time of publication Monday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40854633/oracle-stock-climbs-on-104-billion-fy29-revenue-forecast-what-to-know">Oracle Stock Climbs On $104 Billion FY29 Revenue Forecast: What To Know</a></li>
</ul>
Image: Gerd Altmann from Pixabay

Movers

PLCE

What's Going On With Children's Place Stock Today?

Whales with a lot of money to spend have taken a noticeably bullish stance on Avis Budget Gr.
Looking at options history for Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 42% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $107,520 and 11, calls, for a total amount of $705,127.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $65.0 to $100.0 for Avis Budget Gr over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Avis Budget Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Avis Budget Gr's substantial trades, within a strike price spectrum from $65.0 to $100.0 over the preceding 30 days.
<h3>Avis Budget Gr Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726515035_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$8.6</td>
<td>$8.5</td>
<td>$8.6</td>
<td>$75.00</td>
<td>$130.9K</td>
<td style="text-align: right;">98</td>
<td style="text-align: right;">214</td>
</tr>
<tr>
<td>CAR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$7.0</td>
<td>$73.00</td>
<td>$116.2K</td>
<td style="text-align: right;">330</td>
<td style="text-align: right;">174</td>
</tr>
<tr>
<td>CAR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$9.0</td>
<td>$8.6</td>
<td>$9.0</td>
<td>$70.00</td>
<td>$104.4K</td>
<td style="text-align: right;">200</td>
<td style="text-align: right;">199</td>
</tr>
<tr>
<td>CAR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$9.0</td>
<td>$8.2</td>
<td>$9.0</td>
<td>$70.00</td>
<td>$74.7K</td>
<td style="text-align: right;">200</td>
<td style="text-align: right;">83</td>
</tr>
<tr>
<td>CAR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$26.0</td>
<td>$25.3</td>
<td>$26.0</td>
<td>$75.00</td>
<td>$52.0K</td>
<td style="text-align: right;">104</td>
<td style="text-align: right;">40</td>
</tr>
</tbody>
</table>

<h3>About Avis Budget Gr</h3>
Avis Budget Group Inc is a provider of automotive vehicle rental and car-sharing services. Its brands include Avis, Budget, and Zipcar. Avis is targeted to serve the premium commercial and leisure segments of the travel industry, while Budget is focused on value-conscious customers. The company operates its own network of rental locations and licenses its brands to franchisees. Zipcar is a car-sharing service that allows members to use the company-owned Zipcar fleet at an hourly rate. The company's largest region by revenue is the Americas.
After a thorough review of the options trading surrounding Avis Budget Gr, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Avis Budget Gr</h3>
<ul>
<li>Currently trading with a volume of 504,694, the CAR's price is up by 4.22%, now at $79.58. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Avis Budget Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Avis Budget Gr's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HCA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for HCA Healthcare.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 12%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $91,353, and 13 are calls, for a total amount of $911,865.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $310.0 to $420.0 for HCA Healthcare over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for HCA Healthcare's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across HCA Healthcare's significant trades, within a strike price range of $310.0 to $420.0, over the past month.
<h3>HCA Healthcare Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726515029_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$73.4</td>
<td>$71.9</td>
<td>$71.9</td>
<td>$335.00</td>
<td>$224.7K</td>
<td style="text-align: right;">155</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$56.3</td>
<td>$54.6</td>
<td>$54.73</td>
<td>$355.00</td>
<td>$171.5K</td>
<td style="text-align: right;">38</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$54.5</td>
<td>$54.4</td>
<td>$54.5</td>
<td>$350.00</td>
<td>$81.7K</td>
<td style="text-align: right;">15</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$73.7</td>
<td>$72.6</td>
<td>$73.15</td>
<td>$335.00</td>
<td>$80.4K</td>
<td style="text-align: right;">155</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$56.6</td>
<td>$55.4</td>
<td>$56.0</td>
<td>$355.00</td>
<td>$61.6K</td>
<td style="text-align: right;">38</td>
<td style="text-align: right;">50</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
Following our analysis of the options activities associated with HCA Healthcare, we pivot to a closer look at the company's own performance.
<h3>Where Is HCA Healthcare Standing Right Now?</h3>
<ul>
<li>With a trading volume of 471,571, the price of HCA is up by 2.28%, reaching $403.0.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 36 days from now.</li>
</ul>
<h3>What The Experts Say On HCA Healthcare</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $409.2.
<ul>
<li>Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on HCA Healthcare with a target price of $430. </li>
<li>Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for HCA Healthcare, targeting a price of $405. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $392. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $392. </li>
<li>In a cautious move, an analyst from Morgan Stanley downgraded its rating to Equal-Weight, setting a price target of $427. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HCA Healthcare options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Check Out What Whales Are Doing With HCA

Deep-pocketed investors have adopted a bearish approach towards Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ENPH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Enphase Energy. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 20% leaning bullish and 80% bearish. Among these notable options, 5 are puts, totaling $460,945, and 5 are calls, amounting to $219,919.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $185.0 for Enphase Energy during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Enphase Energy's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Enphase Energy's significant trades, within a strike price range of $90.0 to $185.0, over the past month.
<h3>Enphase Energy Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726515024_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$8.2</td>
<td>$7.95</td>
<td>$8.2</td>
<td>$90.00</td>
<td>$246.0K</td>
<td style="text-align: right;">127</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$29.7</td>
<td>$29.2</td>
<td>$29.7</td>
<td>$130.00</td>
<td>$112.9K</td>
<td style="text-align: right;">62</td>
<td style="text-align: right;">38</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$10.6</td>
<td>$10.4</td>
<td>$10.45</td>
<td>$105.00</td>
<td>$82.5K</td>
<td style="text-align: right;">454</td>
<td style="text-align: right;">82</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$10.25</td>
<td>$9.05</td>
<td>$10.0</td>
<td>$105.00</td>
<td>$45.0K</td>
<td style="text-align: right;">327</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.85</td>
<td>$12.55</td>
<td>$12.69</td>
<td>$185.00</td>
<td>$38.9K</td>
<td style="text-align: right;">562</td>
<td style="text-align: right;">32</td>
</tr>
</tbody>
</table>

<h3>About Enphase Energy</h3>
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
In light of the recent options history for Enphase Energy, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Enphase Energy</h3>
<ul>
<li>Trading volume stands at 1,216,940, with ENPH's price up by 2.23%, positioned at $112.36.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 38 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Enphase Energy, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ENPH

Spotlight on Enphase Energy: Analyzing the Surge in Options Activity

Brunswick Corporation&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bc#NYSE">BC</a>) Freedom Boat Club, the world&#39;s largest boat club network, acquired the South Florida franchise operations and territory. The acquisition adds 13 corporate locations from Pompano Beach to Stuart, FL, accelerating the company&#39;s growth and expanding its corporate presence along the Southeast Florida coastline. Brunswick&#39;s shares moved up 4.4% during trading hours on Sept. 13, 2024.
Situated near Freedom Boat Club&#39;s existing corporate locations in Fort Lauderdale, Miami, and Islamorada, the acquisition enhances its operational efficiencies. This is one of the company&#39;s largest additions, covering Broward, Palm Beach, and Martin counties. It intends to build on the strong foundation laid by the former franchise owner while continuing to provide outstanding experiences for its members.
The addition of the South Florida franchise offers a key opportunity to accelerate growth in a year-round boating region while also leveraging synergies with Brunswick&#39;s family of brands.
<h2>FBC Expansion Drives BC&#39;s Growth</h2>
Brunswick Corporation leads the marine recreation industry with innovations that enhance water experiences. The company&#39;s Boat segment includes the Brunswick Boat Group, which manufactures and distributes recreational boats, and Business Acceleration. Brunswick significantly expanded FBC since acquiring it in 2019, growing from 170 to more than 415 locations across North America, Europe and Australia.
During second-quarter 2024, the Boat segment delivered steady results despite planned reductions in wholesale orders. Channel partners remain cautious with their orders, but the impact of modest model-year pricing and share gains offset some of the softness.
FBC contributed about 10% to the Boat segment&#39;s revenues and experienced steady membership growth despite macroeconomic uncertainty. The club also expanded with two new flagship locations in Denmark and the UK and recorded 200,000 member trips during the quarter. Discounting and promotional activities remain high, especially for prior model year products, to boost retail sales. Investments in digital platforms continue to benefit the company, with nearly 40% of FBC membership sales in the quarter being digitally assisted.
<h2>BC&#39;s Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/b0/77829.jpg?v=386916374" />
Image Source: Zacks Investment Research
Shares of Brunswick have increased 5.9% in the past three months compared with the industry&#39;s 6.3% rise. The company is likely to benefit from new model introductions and marketing and promotional activities. Also, the emphasis on expansion bodes well.
Continued slower retail sales and higher discounting and carrying costs are a concern. Owing to these headwinds, the company expects full-year unit retail sales to decline by approximately 10% compared with the original forecast of flat sales.
<h2>Zacks Rank &amp; Key Picks</h2>
Brunswick currently carries a Zacks Rank #5 (Strong Sell).
Here are some better-ranked stocks from the Consumer Discretionary sector.
Royal Caribbean Cruises Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcl#NYSE">RCL</a>) currently sports a Zacks Rank #1 (Strong Buy).
RCL has a trailing four-quarter earnings surprise of 18.5%, on average. The stock has gained 75.1% in the past year. The Zacks Consensus Estimate for RCL&#39;s 2024 sales and earnings per share indicates growth of 18.1% and 71.1%, respectively, from the year-ago levels.
DoubleDown Interactive Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddi#NASDAQ">DDI</a>) currently sports a Zacks Rank of 1. DDI has a trailing four-quarter earnings surprise of 22.1%, on average. The stock has increased 41.8% in the past year.
The Zacks Consensus Estimate for DDI&#39;s 2024 sales and EPS indicates an increase of 12.6% and 15.8%, respectively, from the year-ago levels.
Norwegian Cruise Line Holdings Ltd. currently sports a Zacks Rank of 1. NCLH has a trailing four-quarter earnings surprise of 5.7%, on average. The stock has moved up 12.9% in the past year.
The Zacks Consensus Estimate for NCLH&#39;s 2024 sales and EPS indicates an increase of 9.8% and 125.7%, respectively, from the year-ago levels.
<a href="https://www.zacks.com/stock/news/2336688/bc-s-freedom-boat-club-expands-south-florida-operations?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2336688">To read this article on Zacks.com click here.</a>

Retail Sales

BC's Freedom Boat Club Expands South Florida Operations

Central Pacific Reportedly Nearing Deal To Acquire Hawaiian Electric's Bank; A Sale Would Help Hawaiian Electric's Finances After Maui Fire; Warburg, Centerbridge, Atlas Are Said In Talks To Fund Deal

Accenture plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acn#NYSE">ACN</a>) has seen its stock rise 22% in the past three months, outperforming the industry&#39;s 14.9% growth and the 2.4% uptick in the S&amp;P 500 composite index.
We have a Zacks Rank #2 (Buy) on ACN shares, given the company&#39;s technological prowess, strong cash position, contribution from acquisitions and consistent dividend payouts.
<div class="chart_embed">
<h2>Accenture PLC Price</h2>
<img alt="Accenture PLC Price" src="https://staticx-tuner.zacks.com/images/charts/4f/1726492889.png" style="height:310px; width:600px" title="" />
Accenture PLC price | Accenture PLC Quote
Let&#39;s look at the factors in detail that make the stock an attractive pick.
</div>
<h2>Technology-Based Growth Strategy</h2>
Accenture&#39;s broader growth strategy focuses on delivering comprehensive value to its stakeholders through technology. By focusing on building a digital core with cloud, data, and AI technologies and investing in talent, Accenture is well-positioned for long-term success. We believe this strategy positions Accenture as a trusted partner for its clients and keeps the stock attractive.
<h2>Strong Cash Position</h2>
Accenture had a cash and cash equivalents balance of $5.5 billion at the end of third-quarter fiscal 2024 against a total long-term debt of just $69 million. Cash provided by operating activities was $1 billion and free cash flow came in at $1 million. Accenture generates&nbsp;significant cash from operations&nbsp;and also holds a huge cash balance, management has the flexibility to pursue growth in any areas that exhibit true potential.
This flexibility and technological prowess allowed it to pursue acquisition opportunities in different markets. The company spent $2.5 billion across 25 acquisitions in fiscal 2023.&nbsp;A disciplined acquisition strategy&nbsp;helps ACN channel its business in high-growth areas, adding skills and capabilities, and deepening industry and functional expertise.
<h2>Dividend Spinner</h2>
Commitment to shareholder returns makes ACN a reliable way for investors to compound wealth over the long term. The company paid $2.8 billion, $2.5 billion and $2.2 billion in dividends in 2023, 2022, and 2021, respectively. We are expecting steady income growth, which will translate to steady cash flow, enabling it to pay out stable dividends.
<h2>Other Stocks to Consider</h2>
Investors can look at&nbsp;some other top-ranked stocks like AppLovin&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>), Climb Global Solutions (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clmb#NASDAQ">CLMB</a>), and HNI Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hni#NYSE">HNI</a>).
APP currently sports a Zacks Rank of 1 (Strong Buy). The company has a long-term earnings growth expectation of 20%. APP delivered a trailing four-quarter earnings surprise of 21.1%, on average.
Climb Global Solutions flaunts a Zacks Rank #1 at present. It has a long-term earnings growth expectation of 11%. CLMB delivered a trailing four-quarter earnings surprise of 25.2%, on average.
HNI sports a Zacks Rank #1 at present. It has a long-term earnings growth expectation of 12%. HNI delivered a trailing four-quarter earnings surprise of 51.3%, on average.
<a href="https://www.zacks.com/stock/news/2336610/here-s-why-you-should-add-accenture-stock-to-your-portfolio?cid=CS-BENZ-FT-analyst_blog|rank_focused-2336610">To read this article on Zacks.com click here.</a>

Dividends

Management

Tech

CLMB

Here's Why You Should Add Accenture Stock to Your Portfolio

Financial giants have made a conspicuous bullish move on MicroStrategy. Our analysis of options history for MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) revealed 145 unusual trades.
Delving into the details, we found 44% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 35 were puts, with a value of $2,123,015, and 110 were calls, valued at $14,926,000.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.5 to $380.0 for MicroStrategy over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for MicroStrategy's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of MicroStrategy's whale activity within a strike price range from $10.5 to $380.0 in the last 30 days. 
<h3>MicroStrategy Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726514143_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$34.55</td>
<td>$34.1</td>
<td>$34.41</td>
<td>$123.00</td>
<td>$1.7M</td>
<td>43</td>
<td style="text-align: right;">501</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$54.15</td>
<td>$52.85</td>
<td>$53.05</td>
<td>$140.00</td>
<td>$1.0M</td>
<td>520</td>
<td style="text-align: right;">241</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$53.65</td>
<td>$52.65</td>
<td>$52.73</td>
<td>$140.00</td>
<td>$358.3K</td>
<td>520</td>
<td style="text-align: right;">632</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$22.5</td>
<td>$22.45</td>
<td>$22.45</td>
<td>$120.00</td>
<td>$223.9K</td>
<td>2.2K</td>
<td style="text-align: right;">81</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$54.15</td>
<td>$52.85</td>
<td>$53.04</td>
<td>$140.00</td>
<td>$196.2K</td>
<td>520</td>
<td style="text-align: right;">294</td>
</tr>
</tbody>
</table>

<h3>About MicroStrategy</h3>
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.
In light of the recent options history for MicroStrategy, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of MicroStrategy</h3>
<ul>
<li>Trading volume stands at 7,277,458, with MSTR's price down by -4.28%, positioned at $135.41.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 44 days.</li>
</ul>
<h3>What The Experts Say On MicroStrategy</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $171.0.
<ul>
<li>Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for MicroStrategy, targeting a price of $173. </li>
<li>An analyst from Barclays downgraded its action to Overweight with a price target of $146. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $194. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for MicroStrategy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

MSTR

Market Whales and Their Recent Bets on MSTR Options

Whales with a lot of money to spend have taken a noticeably bullish stance on Pinterest.
Looking at options history for Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $657,391 and 3, calls, for a total amount of $134,038.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $24.0 to $31.0 for Pinterest over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pinterest's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pinterest's whale trades within a strike price range from $24.0 to $31.0 in the last 30 days. 
<h3>Pinterest Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726514138_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.0</td>
<td>$5.95</td>
<td>$5.99</td>
<td>$30.00</td>
<td>$176.2K</td>
<td>2.1K</td>
<td>1.2K</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.0</td>
<td>$5.9</td>
<td>$5.95</td>
<td>$30.00</td>
<td>$167.1K</td>
<td>2.1K</td>
<td>567</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.0</td>
<td>$5.9</td>
<td>$5.95</td>
<td>$30.00</td>
<td>$102.9K</td>
<td>2.1K</td>
<td>750</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$5.95</td>
<td>$5.85</td>
<td>$5.9</td>
<td>$30.00</td>
<td>$77.8K</td>
<td>2.1K</td>
<td>132</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.35</td>
<td>$6.05</td>
<td>$6.25</td>
<td>$30.00</td>
<td>$62.5K</td>
<td>483</td>
<td>202</td>
</tr>
</tbody>
</table>

<h3>About Pinterest</h3>
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from cooking recipes to travel destinations. Founded in 2010, the platform consists of a largely female audience, which accounts for roughly two thirds of its nearly 500 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features. About 20% of users reside in the US and Canada, but the region accounted for about 80% of revenue in 2023.
In light of the recent options history for Pinterest, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Pinterest</h3>
<ul>
<li>Currently trading with a volume of 4,316,115, the PINS's price is up by 0.12%, now at $28.89. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 42 days.</li>
</ul>
<h3>Expert Opinions on Pinterest</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $44.666666666666664.
<ul>
<li>An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $48. </li>
<li>An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $45. </li>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $41.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pinterest options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

PINS

Decoding Pinterest's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 34 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 38% leaning bullish and 44% bearish. Among these notable options, 10 are puts, totaling $1,172,743, and 24 are calls, amounting to $1,541,432.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $350.0 to $640.0 for UnitedHealth Group over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for UnitedHealth Group's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UnitedHealth Group's whale activity within a strike price range from $350.0 to $640.0 in the last 30 days. 
<h3>UnitedHealth Group Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726514134_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$22.6</td>
<td>$22.15</td>
<td>$22.45</td>
<td>$590.00</td>
<td>$785.7K</td>
<td>338</td>
<td style="text-align: right;">353</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/01/24</td>
<td>$47.4</td>
<td>$45.45</td>
<td>$46.4</td>
<td>$555.00</td>
<td>$232.0K</td>
<td>0</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$93.65</td>
<td>$91.8</td>
<td>$91.8</td>
<td>$520.00</td>
<td>$229.5K</td>
<td>1.1K</td>
<td style="text-align: right;">25</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$35.1</td>
<td>$34.25</td>
<td>$35.1</td>
<td>$570.00</td>
<td>$175.5K</td>
<td>0</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.35</td>
<td>$3.3</td>
<td>$3.35</td>
<td>$640.00</td>
<td>$141.2K</td>
<td>174</td>
<td style="text-align: right;">418</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Following our analysis of the options activities associated with UnitedHealth Group, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of UnitedHealth Group</h3>
<ul>
<li>With a volume of 1,271,110, the price of UNH is down -0.48% at $589.39. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $591.0.
<ul>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $591. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $591. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $591. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

What the Options Market Tells Us About UnitedHealth Group

REPL

Replimune Group shares are trading lower. The company announced its primary analysis results from its IGNYTE clinical trial of PR1 in combination with Nivulumab for anti-PBD resistant melanoma at the 2024 ESMO Congress.

TIXT

TELUS Invests $9.6M In Chaudière-Appalaches Region To Expand Wireless Connectivity, Supported By $2.7M From Quebec Government And $2.2M From CRTC For 20 New 5G Sites

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2262

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2048

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2186

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2029

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2054

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2113

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2184

BondBloxx BB Rated USD High Yield Corporate Bond declares monthly distribution of $0.2113

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2190

BondBloxx BB Rated USD High Yield Corporate Bond ETF declares monthly distribution of $0.2161

BondBloxx BB-Rated USD High Yield Corporate Bond ETF

Editor&#39;s note: This story has been corrected to reflect that the&nbsp;FDA deferred action on&nbsp;Amicus Therapeutics&#39; Biologics License Application.&nbsp;

October proved to be a mixed month for the Food and Drug Administration&rsquo;s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the year-to-date period to 28.

Among the NME approvals were Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) unit Janssen&rsquo;s <a href="https://www.benzinga.com/general/biotech/22/10/29411082/fda-approves-johnson-johnsons-ready-to-use-cell-therapy-for-multiple-myeloma">Tecvayli, a BCMA-targeting bispecific, for treating multiple myeloma </a>in patients who have tried at least four prior lines of therapy. AstraZeneca plc&rsquo;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) tremelimumab-durvalumab combo received the nod for treating adult patients with inoperable hepatocellular carcinoma.

The FDA deferred action on Amicus Therapeutics, Inc.&#39;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) two-component drug for treating Pompe disease, characterized by severe muscle weakness, due to an inability to inspect a manufacturing site in China before the PDUFA goal date.

The site could not be inspected due to COVID-19 travel restrictions, according to a company press release.&nbsp;

&ldquo;We are now one step away from the necessary approvals for AT-GAA in the U.S. We continue to believe this is a question of &lsquo;when&rsquo; not &lsquo;if&rsquo; AT-GAA will be approved and we will continue to work with great urgency to support the FDA&rsquo;s completion of the final plant inspection necessary for approval so that this important new treatment option is made available for people living with Pompe disease in the United States,&rdquo; Bradley Campbell, Amicus president&nbsp;and CEO, said in a statement.&nbsp;

Adcom decisions were mostly negative, with a&nbsp;panel postponing the meeting scheduled for discussing Ispen S.A.&rsquo;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IPSEY#OTC">IPSEY</a>) palovarotene capsules to treat a condition in which muscle and connective tissue such as tendons and ligaments will be gradually replaced by bones. Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>)<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/10/29484841/analysts-slash-y-mabs-therapeutics-price-targets-as-uncertainty-looms-over-neurobla"> plunged about 60% on Monday on a negative Adcom verdict.</a>

A PDUFA, or Prescription Drug User Fee Act, date is the deadline fixed by the FDA to announce its verdict regarding the approvability or non-approvability of a drug. It is a binary catalyst that can trigger big stock swings.

Seagen Seeks Another Label Expansion For Its Blood Cancer Drug 

<ul>
	<li>Company: Seagen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGEN#NASDAQ">SGEN</a>)</li>
	<li>Type of Application: supplemental biologic license application</li>
	<li>Candidate: Adcetris</li>
	<li>Indication: treatment-na&iuml;ve Hodgkin&rsquo;s lymphoma in adults</li>
	<li>Date: Nov. 16</li>
</ul>

Adcetris was first approved by the FDA in 2011 for treating Hodgkin&rsquo;s lymphoma and a rare lymphoma called systemic anaplastic large-cell lymphoma. It subsequently received five label expansions, with the last one secured in November 2018.

Seagen is now seeking another expanded use for the drug. Adcetris is being evaluated in children and young adults with previously untreated, high-risk Hodgkin lymphoma.

In the recent quarter that ended in September, Adcetris fetched sales of $428 billion, up 17% year-over-year.

Can Travere Win FDA Nod For Rare Kidney Disorder Drug?

<ul>
	<li>Company: Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>)/Ligand Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>)</li>
	<li>Type of Application: new drug application</li>
	<li>Candidate: sparsentan</li>
	<li>Indication: IgA nephropathy</li>
	<li>Date:&nbsp;Feb.&nbsp;17, 2023</li>
</ul>

Travere announced the&nbsp;FDA&rsquo;s acceptance of the regulatory application for priority review on May 16. The company said, if approved, sparsentan would be the first FDA-approved non-immunosuppressive treatment option for IgA nephropathy, or IgAN.

IgAN, aka Berger&rsquo;s disease, is a rare kidney disorder characterized by the build-up of immunoglobin, which causes a breakdown of the normal filtering mechanisms, leading to blood and protein in the urine. It is the leading cause of primary glomerulonephritis, an end-stage kidney disease. More than 100,000 people in the U.S. are estimated to be suffering from the disorder.

Travere in-licensed the drug from Ligand, and an NDA submission by Travere will kick in a potential milestone payment of about $5.9 million for Ligand.

Provention Shrugs Off Hiccups And Looks To Take Its Diabetes Drug Past Finish Line: 

<ul>
	<li>Company: Provention Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVB#NASDAQ">PRVB</a>)/MacroGenics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>)</li>
	<li>Type of Application: BLA</li>
	<li>Candidate: teplizumab</li>
	<li>Indication: type 1 diabetes mellitus</li>
	<li>Date: Nov. 17</li>
</ul>

Provention Bio&rsquo;s teplizumab was in-licensed from MacroGenics and it is being evaluated as an option for delaying Type 1 diabetes in at-risk individuals. In July 2021, the original application was handed down a complete response letter, which cited issues with the bridging study done comparing the drug and its predecessor drug from Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).

The company resubmitted the application in January 2022, and it was accepted for review in March with a new PDUFA goal date of Aug. 17. In late June, the regulator came back and said it is extending the review period by three months.

Will FDA Overlook Panel Verdict On Spectrum&rsquo;s Lung Cancer Drug? 

<ul>
	<li>Company: Spectrum Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPI#NASDAQ">SPPI</a>)</li>
	<li>Type of Application: NDA</li>
	<li>Candidate: poziotinib</li>
	<li>Indication: lung cancer</li>
	<li>Date: Nov. 24</li>
</ul>

Poziotinib is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration. Spectrum&rsquo;s NDA seeks approval of the drug for patients with previously-treated, locally-advanced or metastatic non-small cell lung cancer with HER2 exon 20 insertion mutations.

There is no FDA-approved therapy for this condition. The product has a Fast Track designation. An FDA panel, which reviewed the drug in late September, voted 9-4 that its benefits do not outweigh the risks.

&lsquo;Go&rsquo; or &lsquo;no-Go&rsquo; For Apellis&rsquo; Eye Disorder Drug? 

<ul>
	<li>Company: Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>)</li>
	<li>Type of Application: NDA</li>
	<li>Candidate: intravitreal pegcetacoplan</li>
	<li>Indication: geographic atrophy</li>
	<li>Date: Nov. 26</li>
</ul>

Waltham, Massachusetts-based Apellis announced in July that the FDA accepted the application for review. Pegcetacoplan is a C3 therapy being evaluated for the treatment of GA secondary to age-related macular degeneration.

Apellis said, citing estimates, that GA affects more than five million people worldwide and is the leading cause of blindness. It also noted that there is no currently approved therapy for GA.

See also:&nbsp;<a href="https://www.benzinga.com/general/biotech/22/10/29461060/during-the-pandemic-tuberculosis-deaths-increased-reversing-years-of-decline-who-report">During The Pandemic Tuberculosis Deaths Increased, Reversing Years Of Decline: WHO Report</a>

ImmunoGen Knocks FDA Altar For Antibody-Drug Conjugate To Treat Ovarian Cancer

<ul>
	<li>Company: ImmunoGen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMGN#NASDAQ">IMGN</a>)</li>
	<li>Type of Application: BLA</li>
	<li>Candidate: mirvetuximab soravtansine monotherapy</li>
	<li>Indication: ovarian cancer</li>
	<li>Date: Nov. 28</li>
</ul>

Mirvetuximab soravtansine is an investigational antibody drug conjugate that selectively kills cancer cells. It is being investigated as a monotherapy in patients with folate alpha-high platinum-resistant ovarian cancer who have been previously treated with one to three systemic treatments.

The FDA accepted ImmunoGen&rsquo;s BLA for review in late May.

SCYNEXIS Seeks To Expand The Use Of Vaginal Yeast Infection Drug: 

<ul>
	<li>Company: SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>)</li>
	<li>Type of Application: sNDA</li>
	<li>Candidate: Brexafemme</li>
	<li>Indication: vulvovaginal candidiasis</li>
	<li>Date: Nov. 30</li>
</ul>

Brexafemme is a novel oral antifungal approved for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection, in August. The company has now applied for approval of the same for an expanded indication. This time around, Brexafemme is being tried for the prevention of recurrent vulvovaginal candidiasis.

Can FDA Lift Y-mAbs Stock That Plunged On Adcom Verdict? 

<ul>
	<li>Company:&nbsp;Y-mAbs Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>)</li>
	<li>Type of Application: BLA</li>
	<li>Candidate: omburtamab</li>
	<li>Indication: central nervous system/leptomeningeal metastasis from neuroblastoma.</li>
	<li>Date: Nov. 30</li>
</ul>

FDA&rsquo;s Oncologic Drugs Advisory Committee last week handed down a negative verdict on the application, which has dampened the odds of omburtamab scraping&nbsp;through. The committee voted 16 to 0 that the company had not provided sufficient evidence to conclude that omburtamab improves overall survival. The verdict sent traders scurrying away from the stock, resulting in the 60% plunge.

Nevertheless, the FDA will look into the application; therefore, the PDUFA action date of Nov. 30 stays intact. The regulator typically takes into account Adcom&rsquo;s discussions while making its decision, but is not bound to go with it.

Adcom Calendar 

<ul>
	<li>FDA&#39;s Pulmonary-Allergy Drugs Advisory Committee will discuss the NDA submitted by AstraZeneca and Bond Avillion 2 Development for a fixed dose combination of budesonide and albuterol sulfate metered dose inhaler. The proposed indication is as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older. The meeting is scheduled on Nov. 8, between 10 a.m. EDT and 4 p.m. EDT.</li>
	<li>The same committee will discuss Veru, Inc.&rsquo;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) request for emergency use authorization for sabizabulin oral capsule for treating SARS-CoV-2 infection in hospitalized patients with moderate to severe COVID-19 infection who are at high risk of acute respiratory distress syndrome. The meeting will be held on Nov. 9,&nbsp;between 10 a.m. ET and 4 p.m. ET.</li>
	<li>On Nov. 16, the Cardiovascular and Renal Drugs Advisory Committee will discuss the NDA for tenapanor hydrochloride tablets, submitted by Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) for the control of serum phosphorus levels in adults with chronic kidney disease on dialysis. The Adcom will be held on Nov. 16, between 9:30 a.m. ET and 5 p.m. ET.</li>
</ul>

The iShares Biotechnology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NASDAQ">IBB</a>) was traded 0.94% higher on Tuesday to $129.78, according to<a href="https://benzinga.grsm.io/register174"> Benzinga Pro data.</a>

Read Next:<a href="https://www.benzinga.com/money/best-biotech-stocks"> Best Biotech Socks Right Now</a> 
Correction 11.2.2022:&nbsp;Travere Therapeutics&rsquo; assigned PDUFA date is&nbsp;Feb.&nbsp;17, 2023, not Nov. 17 as originally reported.

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF

News

Latest news for BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF (ARCA:XBB)

Tuesday, November 01, 2022